Loading company…
T-ONE Therapeutics develops RNA therapies for cancer and autoimmune diseases.
Founded in 2022 in Italy, T-ONE Therapeutics researches RNA-based treatments, including LINE1-ASO, an antisense oligonucleotide targeting LINE1-RNA for potential use in immunotherapy. It raised EUR 2.5 million in venture funding from Utopia Sis in September 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in